Abiopharma

🔍 Raymond Christie (Executive)

Company: KOHLS Corp (KSS)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 202 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 280,248.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 65 shares of Common Stock at $12.9 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 280,183.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 386 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 280,569.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 126 shares of Common Stock at $12.9 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 280,443.00 | transaction_form_type: 4 | Footnotes: F4, F5

Footnotes:

• F1: Issuance of additional shares in respect of shares issued in settlement of performance share units in lieu of a $0.125 per share dividend issued by the Company on all common stock, which was payable on April 1, 2026.
• F2: Represents shares used to satisfy tax withholding obligations with respect to issuance of additional shares.
• F3: Issuance of additional shares representing the dividend equivalent amount on vested restricted stock units.
• F4: Represents shares used to satisfy tax withholding obligations upon vesting of restricted stock unit dividend equivalent amounts under the Company's Long-Term Compensation Plan.
• F5: Includes 152,651 unvested restricted stock units.